title: Recombinant tissue plasminogen activator is a useful alternative to heparin in priming quinton permcath.
abstract: Soft, cuffed, implantable central venous catheters such as the Quinton Permcath (Quinton Instrument Co, Seattle, WA) are increasingly used as permanent access in patients with end-stage renal disease. Their major limitations, besides infection, are thrombosis and inadequate blood flow. To prevent those complications, heparin is conventionally used for priming the Quinton Permcath between dialysis sessions. In this study, we compared recombinant tissue plasminogen activator (rTPA) with heparin for priming the Quinton Permcath in a prospective, randomized, crossover design. Twelve patients were randomly assigned to receive 2,000 IU of heparin or 2 mg of rTPA injected into each catheter lumen at the end of each dialysis session over a period of 4 months, followed by a switch to the other substance. Blood flow rate (flow), venous pressure (VP), and arterial pressure (AP) were monitored at each dialysis session hourly. Flow was significantly greater (P = 0.0001) with rTPA (mean +/- SD, 237.7 +/- 18.1 and 231.6 +/- 12.4 mL/min for the first and second 2 months, respectively) compared with heparin (208.5 +/- 10.1 and 206.9 +/- 14.2 mL/min for the first and second 2 months, respectively). VP was significantly less (P = 0.0001) with rTPA (135.4 +/- 8.2 and 140 +/- 15.2 mm Hg for the first and second 2 months, respectively) compared with heparin (160.5 +/- 16.1 and 159.2 +/- 20.7 mm Hg for the first and second 2 months, respectively). AP was significantly greater (P = 0.0002) with rTPA (-113.5 +/- 11.8 and -115.9 +/- 12.7 mm Hg for the first and second 2 months, respectively) compared with heparin (-136.5 +/- 23.3 and -134.7 +/- 25.8 mm Hg for the first and second 2 months, respectively). In addition, fewer complications (flow problems, clotting, and need for fibrinolysis) occurred in the rTPA period. These results show that rTPA is superior to heparin for priming the Quinton Permcath between hemodialysis sessions and can be used as a valuable alternative to conventional heparin in selected patients.
authors.affiliation: Department of Internal Medicine III, Division of Nephrology and Dialysis, University of Vienna, Vienna, Austria. peter.schenk@akh-wien.ac.at
authors.forename: P
authors.initials: P
authors.lastname: Schenk
authors.forename: A R
authors.initials: AR
authors.lastname: Rosenkranz
authors.forename: G
authors.initials: G
authors.lastname: Wölfl
authors.forename: W H
authors.initials: WH
authors.lastname: Hörl
authors.forename: O
authors.initials: O
authors.lastname: Traindl
mesh_terms: D000368:Aged; D001166:Arteriovenous Shunt, Surgical; D001783:Blood Flow Velocity / Q000187:drug effects; D002408:Catheters, Indwelling; D018592:Cross-Over Studies; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects; D006083:Graft Occlusion, Vascular / Q000097:blood / Q000517:prevention & control*; D006493:Heparin / Q000008:administration & dosage* / Q000009:adverse effects; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D006435:Renal Dialysis; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D006495:Heparin, Low-Molecular-Weight; D006493:Heparin; D010959:Tissue Plasminogen Activator